Vaccine development and infectious disease
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Swiss university hospital contributing clinical cohorts, immunoprofiling, and neuroscience expertise to translational EU health research.
“Core partner in EbolaVac, TBVAC2020, EHVA (HIV), PERISCOPE (pertussis), and PEVIA (Pan-Ebola), covering multiple pathogen targets and vaccine platforms.”
PrimaryCH43 projects - ST GEORGE'S HOSPITAL MEDICAL SCHOOL
London medical school specialising in infectious disease vaccines, congenital anomaly surveillance, and plant-based pharmaceutical manufacturing across 42 countries.
“Coordinated EMI-TB (EUR 2.2M) on tuberculosis mucosal immunity, participated in BactiVax training network on antimicrobial-resistant bacteria vaccines, and NeoIPC on infection prevention in neonatal intensive care.”
PrimaryUK17 projects - UNIVERSITY OF MALAWI
Malawi's principal university contributing health systems research, agricultural innovation, and urban development field capacity to European-African consortia.
“Vacc-iNTS advanced a GMMA-based vaccine against invasive non-typhoidal Salmonella through Phase 1 trials, with University of Malawi as a third-party trial site.”
MW8 projects